Spoken Alpha
Apogee Therapeutics, Inc.
Apogee Therapeutics develops novel monoclonal antibodies with extended half-lives targeting inflammatory and immunology indications including atopic dermatitis, asthma, eosinophilic esophagitis, and COPD.
Apogee Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $10.22B market cap.
APGE missed consensus EPS by 0.0% in Q2 FY2026, reported Aug 9, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add APGE, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for APGE.
$ curl https://api.spokenalpha.com/v1/companies/APGEFAQ
Spoken Alpha indexes APGE's earnings call transcripts at https://spokenalpha.com/companies/APGE. Each call links to attributed speakers and parsed analyst Q&A. Apogee Therapeutics, Inc.'s own investor relations page is at https://investors.apogeetherapeutics.com/news-events/news.
Apogee Therapeutics, Inc. (APGE) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | $-1.14 | $-1.10 | -3.6% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-1.06 | $-1.13 | +6.2% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-09 | $-1.03 | $-0.62 | -66.1% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-1.11 | $-1.15 | +3.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-1.13 | $-1.05 | -7.6% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.95 | $-1.19 | +20.2% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-1.18 | $-0.62 | -90.3% | $130.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.86 | $-0.74 | -16.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.60 | $-0.55 | -9.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.64 | $-0.65 | +1.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-04 | $-0.32 | $-0.49 | +34.7% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.51 | $-0.42 | -21.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-27 | $-3.78 | $-1.70 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-30 | $-2.38 | $0.00 | — | $0 | — | — | EODHD |
Source: EODHD. APGE reported actuals as published; sparse fields render as —.